GlycoMimetics, Inc. (GLYC) Financials
Stock symbol GLYC is outdated, potentially delisted? Maybe it is available on other exchange?
GLYC Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2023 | 53.2 million | 6.7 million |
| June 30, 2023 | 61.8 million | 7.0 million |
| March 31, 2023 | 68.9 million | 6.7 million |
| Dec. 31, 2022 | 51.8 million | 8.9 million |
GLYC Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2023 | -8.7 million | 887837 |
| June 30, 2023 | -7.0 million | 858088 |
| March 31, 2023 | -11.6 million | 870180 |
| Dec. 31, 2022 | -7.9 million | 899201 |
GLYC Net Income
No data available :(
GLYC Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2023 | 49.4 million | - | 1.0 million |
| June 30, 2023 | 58.0 million | - | 1.3 million |
| March 31, 2023 | 65.0 million | - | 651734 |
| Dec. 31, 2022 | 47.9 million | - | 918555 |
GLYC Shares Outstanding
GLYC Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2023 | 7866 | 5.3 billion | 4.5 billion | - |
| June 30, 2023 | 10530 | 4.1 million | 4.9 million | - |
| March 31, 2023 | 2197 | 5.4 million | 5.5 million | - |
| Dec. 31, 2022 | 1 | 5.9 million | 4.7 million | - |
GLYC Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2023 | - | 269937 |
| June 30, 2023 | - | 265866 |
| March 31, 2023 | - | 262958 |
| Dec. 31, 2022 | 75 | 259566 |
GLYC
Price: $15.70
52 week price:
Earnings Per Share: -46.00 USD
P/E Ratio: -0.34
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.7 million
Ebitda: -8.1 millionMarket Capitalization: 1.0 billion